Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection

Pan, Tao; Liu, Xiaoyun; Shou-gui, Xiang; Ji, Wenli

doi:10.3892/etm.2016.3051

Cited by 8 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acinetobacter baumannii is an aerobic gram-negative coccobacillus that causes nosocomial pneumonia, bloodstream infections, meningitis, and urinary tract infections (Pan et al 2016). The prevalence of multidrug resistance in A. baumannii isolates in Iran has increased from 50% in 2001 to 2007 to 74% in 2010 to 2015 (Bialvaei et al 2017).…”

Section: Introductionmentioning

confidence: 99%

The frequency of efflux pump genes expression in Acinetobacter baumannii isolates from pulmonary secretions

et al. 2022

View full text Add to dashboard Cite

Acinetobacter baumannii is an important opportunistic pathogen, and the cause of nosocomial infections worldwide in recent decades. Efflux pumps are considered as the important causes of multidrug resistance of A. baumannii. The aim of this study was to determine the frequency of efflux pump genes, and evaluate the antibiotic effect of Tigecycline on the expression of adeB gene in isolates of multidrug-resistant. A. baumannii. 70 isolates of A. baumannii were collected and confirmed by biochemical and molecular tests. Antibiotic resistance (Ciprofloxacin, Trimethoprim-sulfamethoxazole, and Tigecycline) was performed based on the minimum inhibitory concentration (MIC) method. Then, the effect of Carbonyl cyanide m-chlorophenyl hydrazone inhibitor (CCCP) on isolates was investigated and the frequency of adeB, adeG, adeJ and abeM genes were examined by PCR for isolates with reduced in MIC titer. Also, the antibiotic effect of Tigecycline on adeB gene expression in A. baumannii isolates was analyzed by Real-Time PCR. The antibiotic resistance for Ciprofloxacin, Trimethoprim-sulfamethoxazole, and Tigecycline was 97.1%, 95.8% and 37.2%, respectively. Following CCCP inhibitor use, the MIC titer had a decrease in MIC titer containing CCCP inhibitor was 64.3% for Ciprofloxacin, 51.5% for Trimethoprim-sulfamethoxazole and 50% for Tigecycline. The frequencies of genes associated with adeB, adeG, adeJ and abeM efflux pump were 100%, 92.8%, 86% and 98.5%, respectively. Real-Time PCR results showed a correlation between the antibiotic effects of Tigecycline on adeB gene expression. The antibiotic resistance of the isolates was relatively high. The isolates were resistant to Ciprofloxacin and Trimethoprim-sulfamethoxazole antibiotics, while more sensitive to Tigecycline. Also, efflux pump genes, which are the antibiotic resistance factors of A. baumannii, are frequently high in the isolates but it seems that isolates use other effluxe pumps than RND family to exit tigecycline. Graphical Abstract

show abstract

Section: Introductionmentioning

confidence: 99%

The frequency of efflux pump genes expression in Acinetobacter baumannii isolates from pulmonary secretions

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Of these, 47 articles were selected for full-text screening. After excluding 31 articles that did not meet the eligibility criteria, a total of 16 articles were finally included for data extraction and analysis [ 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ].…”

Section: Resultsmentioning

confidence: 99%

Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature

et al. 2023

View full text Add to dashboard Cite

Introduction: Acinetobacter baumannii (AB) is a multidrug-resistant pathogen commonly associated with nosocomial infections. The resistance profile and ability to produce biofilm make it a complicated organism to treat effectively. Cefoperazone sulbactam (CS) is commonly used to treat AB, but the associated data are scarce. Methods: We conducted a systematic review of articles downloaded from Cochrane, Embase, PubMed, Scopus, and Web of Science (through June 2022) to study the efficacy of CS in treating AB infections. Our review evaluated patients treated with CS alone and CS in combination with other antibiotics separately. The following outcomes were studied: clinical cure, microbiological cure, and mortality from any cause. Results: We included 16 studies where CS was used for the treatment of AB infections. This included 11 studies where CS was used alone and 10 studies where CS was used in combination. The outcomes were similar in both groups. We found that the pooled clinical cure, microbiological cure, and mortality with CS alone for AB were 70%, 44%, and 20%, respectively. The pooled clinical cure, microbiological cure, and mortality when CS was used in combination with other antibiotics were 72%, 43%, and 21%, respectively. Conclusions: CS alone or in combination needs to be further explored for the treatment of AB infections. There is a need for randomized controlled trials with comparator drugs to evaluate the drug’s effectiveness.

show abstract

“…TRQ is a type of compound Chinese medicine commonly used in China with clinically proven effectiveness [4][5][6][7][8][9][10]. It is often applied in the treatment of upper and lower respiratory tract infections.…”

Section: Discussionmentioning

confidence: 99%

“…It consists of extracts from Radix Scutellariae baicalensis, bear bile powder, Cornu Caprae Hircus, Flos lonicerae, and Forsythiae Fructus. Because of its ability to clear heat, reduce phlegm, and eliminate toxic effects, this drug is often used to alleviate symptoms such as fever, cough, di culty in expectoration, sore throat, dry mouth, reddish/crimson tongue, and yellow coating on tongue experienced in upper and lower respiratory tract infections and lung diseases [4][5][6][7][8][9][10]. TRQ, as a fast-acting and effective modern medication that comes in ready-to-use formulation, has been used increasingly in clinical situations.…”

Section: Introductionmentioning

confidence: 99%

A Network Pharmacology-based Analysis of the Molecular Mechanism of Tanreqing in the Treatment of the Coronavirus Disease 2019 (COVID-19)

Yang

Wen

Zheng

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: This paper discusses the molecular mechanism of Tanreqing (TRQ) in the treatment of the coronavirus disease 2019 (COVID-19) using the network pharmacology approach. Our study provides new ideas on the laboratory research and clinical treatment of the disease. Method: Information on the chemical constituents of TRQ and the genes targeted by the disease was collected. The common gene targets of the drug and the disease were input into the Search Tool for the Retrieval of Interacting Genes/Proteins（STRING）database to understand the interaction among target proteins. The protein–protein interaction (PPI) network and a network of the chemical constituents of TRQ and their targets were constructed using Cytoscape. Gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed using the R program and other relevant software packages. Results: Twenty-eight active chemical constituents and 365 gene targets were identified for TRQ. Out of these genes, 113 were also found to be involved in the pathogenesis of the disease. Enrichment analysis revealed the therapeutic role that TRQ could have played in the treatment of COVID-19, via the regulation of important pathways such as the renin–angiotension system, neuroactive ligand–receptor interaction, phospholipase D (PLD) signaling pathway, calcium signaling pathway, and the hypoxia-inducible factor 1 (HIF-1) signaling pathway. Conclusions: This study attempts to predict the molecular mechanism of TRQ in the treatment of COVID-19, and suggests TRQ intervention through multiple targets and pathways in processes including inflammatory response, immune regulation, and apoptosis during the treatment of the disease. This study indicates the potential rational application of TRQ in the clinical treatment of COVID-19.

show abstract

Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection

Cited by 8 publications

References 17 publications

The frequency of efflux pump genes expression in Acinetobacter baumannii isolates from pulmonary secretions

The frequency of efflux pump genes expression in Acinetobacter baumannii isolates from pulmonary secretions

Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature

A Network Pharmacology-based Analysis of the Molecular Mechanism of Tanreqing in the Treatment of the Coronavirus Disease 2019 (COVID-19)

Contact Info

Product

Resources

About